KeyBanc raised the firm’s price target on Conmed to $141 from $131 and keeps an Overweight rating on the shares, citing higher estimates and shift to 2025 valuation. Results and upwardly revised guidance reflected macro strength, as well as core growth drivers, and the firm was encouraged it proactively addressed potential competition for AirSeal.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CNMD: